Dear All,You may recall that in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A description of the desired attributes of a drug) as guides for developers (see the 1 Sep 2019 newsletter for the original call for input and the link to the final set of TPPs). These initial TPPs covered:Enteric feverGonorrheaNeonatal sepsisUrinary tract infectionsBased on the 2024 BPPL (Bacterial Priority Pathogen List (see https://amr.solutions/pathogens-and-pipelines/ for the BPPL as well as a PowerPoint deck summarizing all PPLs to date), WHO have now developed a further set of TPPs for three syndromes with particularly high levels of unmet need due to associated mortality and morbidity:Severe infections caused by multidrug-resistant Gram-negative bacteriaThe focus here is on novel antibiotics for bloodstream infections and hospital-acquired or ventilator-associated bacterial pneumonia caused by cephalosporin- and carbapenem-resistant Enterobacterales as well as carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.Therapy of antibiotic-resistant Gram-positive infections in immunosuppressed and critically ill patientsThe focus here is on novel antibiotics for severe infections, including bloodstream infections, caused by vancomycin-resistant enterococci (VRE), including vancomycin-resistant E. faecium (VREF).Community-acquired and healthcare-associated bacterial meningitisThe focus here is on novel antibiotics for community-acquired meningitis caused by penicillin- and cephalosporin-resistant bacteria as well as healthcare-associated (e.g., neurosurgical) meningitis caused by...